38 results
8-K
EX-99.2
IMCR
Immunocore Holdings plc
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
Largest metastatic lesion OS Hazard ratio M1a (<3.0 cm) 0.36 M1b (3.1-8.0 cm) 0.71 M1c (≥8.1 cm) 0.76
Treatment phase Follow-up 1:1
6-K
EX-99.1
IMCR
Immunocore Holdings plc
5 Jun 23
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
9:20am
demonstrated an unprecedented OS benefit with a Hazard Ratio (HR) in the intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI: 0.37, 0.71); p
6-K
EX-99.1
IMCR
Immunocore Holdings plc
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
-positive adult patients with previously untreated mUM. KIMMTRAK demonstrated an unprecedented OS benefit with a Hazard Ratio (HR) in the intent-to-treat
6-K
EX-99.1
IMCR
Immunocore Holdings plc
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
with a Hazard Ratio (HR) in the intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI: 0.37, 0.71); p< 0.0001, over investigator’s choice (82
6-K
EX-99.4
IMCR
Immunocore Holdings plc
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
estate is located in a Special Flood Hazard Area, Federal Flood Insurance, (iii) within sixty (60) days after such acquisition (or such longer period … a hazard to the health and safety of the owners, occupants or any Persons in the vicinity of any Facility or to the indoor or outdoor environment
6-K
EX-99.3
0n0szito2sre1g4gz8
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
9e0vrn hyezp0y6
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
slssvd26kzdgg6b fm9
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
k0zoql9eof5girg3
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.2
qa98sme
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.2
o7z7cw3
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.3
9mfk3
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.4
010k19hy
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
06kkcnub nnru5
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
owvi9kck4tv09k8 h4
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.3
jv6vmxehwk
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
9bbo5rzmo1
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
bja1pqda4mpqd z9ump
5 May 22
Prospectus with selling stockholder info
12:00am
F-3ASR
nfccnbydnouqs
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
eo2j h61m
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm